MANE.US Veradermics, Incorporated
- Market cap
- USD 5.47B
- P/E
- -
- P/B
- 6.87x
- ROE
- -12.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is MANE.US undervalued?
Graham numberThe Graham number of Veradermics, Incorporated cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Veradermics, Incorporated fundamental analysis
No fundamental analysis for Veradermics, Incorporated yet.
Veradermics, Incorporated stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Veradermics, Incorporated
Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. The company's products include VDPHL01, an oral, non-hormonal treatment for men and women with PHL for chronic hair loss therapy. Additionally, it engages in the development of VDMN, a dissolvable microarray patch technology for immunother…
Full company profileVeradermics, Incorporated financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Veradermics, Incorporated annual financial statements
| Item | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | 0.00 | 0.00 | 0.00 | - |
| Operating Income | -17.3M | -26.8M | -72.3M | -118M |
| EBITDA | -16.5M | -25.9M | -70.0M | -104M |
| Net Income | -16.5M | -26.5M | -70.0M | -95.6M |
| EPS | -0.08 | -36 | -94 | -2.27 |
| Balance Sheet | ||||
| Total Assets | 18.5M | 59.4M | 153M | 807M |
| Total Liabilities | 3.84M | 4.72M | 274M | 10.7M |
| Shareholders' Equity | 14.6M | 54.7M | -121M | 796M |
| Cash & Short-term Investments | 16.3M | 53.1M | 142M | 798M |
| Total Debt | 786K | - | 4.00K | 668K |
| Cash Flow | ||||
| Operating Cash Flow | -13.5M | -23.7M | -71.6M | -78.1M |
| Capital Expenditure | 0.00 | 0.00 | 24.0K | 489K |
| Free Cash Flow | -13.5M | -23.7M | -71.6M | -78.6M |
| Ratios | ||||
| ROE | -112.8% | -48.5% | - | -12.0% |
| ROA | -89.3% | -44.6% | -45.9% | -11.8% |
| Debt to Equity | 0.05x | - | - | 0.00x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Veradermics, Incorporated dividends
Veradermics, Incorporated has not paid dividends in the last 3 fiscal years.
Who owns Veradermics, Incorporated
- Insiders 3.84%
- Institutions 96.16%
- Public & others 0.00%
- Shares outstanding 42.2M
- Free float 32.7M
Top funds holding MANE.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 801K | 1.90% | +29.16% | Sep 2026 |
| Fidelity Growth Company Fund | 771K | 1.83% | 0.00% | Aug 2026 |
| JPMorgan Growth Advantage A | 685K | 1.62% | +41.06% | Sep 2026 |
| iShares Russell 2000 ETF | 561K | 1.33% | 0.00% | Oct 2026 |
| JPMorgan Mid Cap Growth I | 430K | 1.02% | +38.28% | Sep 2026 |
| MEDICAL BioHealth EUR Acc | 362K | 0.86% | +0.02% | Aug 2026 |
| abrdn Healthcare Opportunities | 326K | 0.77% | 0.00% | Sep 2026 |
| abrdn Healthcare Investors | 256K | 0.61% | -25.36% | Oct 2026 |
| Fidelity Small Cap Index | 238K | 0.57% | +0.14% | Aug 2026 |
| Fidelity Growth Company K6 | 218K | 0.52% | 0.00% | Aug 2026 |
| Fidelity Worldwide | 208K | 0.49% | 0.00% | Sep 2026 |
| JPMorgan Small Cap Growth A | 207K | 0.49% | -10.76% | Sep 2026 |
| PGIM Jennison Small Company A | 197K | 0.47% | -7.96% | Sep 2026 |
| Fidelity Series Growth Company | 188K | 0.45% | -3.33% | Aug 2026 |
| abrdn World Healthcare | 177K | 0.42% | 0.00% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 166K | 0.39% | +0.23% | Oct 2026 |
| JPMorgan Active Growth ETF | 166K | 0.39% | 0.00% | Oct 2026 |
| Fidelity Blue Chip Growth | 164K | 0.39% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 144K | 0.34% | +46.35% | Sep 2026 |
| iShares Russell 2000 Growth ETF | 143K | 0.34% | -0.38% | Oct 2026 |
Top institutions holding MANE.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Suvretta Capital Management, LLC | 4.17M | 9.88% | 0.00% | Jun 2026 |
| FMR Inc | 3.20M | 7.60% | +78.76% | Jun 2026 |
| SR ONE CAPITAL MANAGEMENT, LP | 2.40M | 5.69% | 0.00% | Jun 2026 |
| Deep Track Capital, LP | 2.00M | 4.74% | +300.00% | Jun 2026 |
| Citadel Advisors Llc | 1.88M | 4.45% | +2.85% | Jun 2026 |
| Siren, L.L.C. | 1.66M | 3.92% | +9.96% | Jun 2026 |
| BlackRock Inc | 1.59M | 3.78% | +463.95% | Jun 2026 |
| Viking Global Investors LP | 1.56M | 3.70% | -7.63% | Jun 2026 |
| JPMorgan Chase & Co | 1.17M | 2.76% | +19.40% | Jun 2026 |
| D. E. Shaw & Co LP | 1.01M | 2.40% | +655.22% | Jun 2026 |
| Aberdeen Group PLC | 992K | 2.35% | -9.51% | Sep 2026 |
| Vanguard Capital Management, LLC | 869K | 2.06% | +24.24% | Jun 2026 |
| Maverick Capital Ltd | 790K | 1.87% | 0.00% | Jun 2026 |
| Jennison Associates LLC | 749K | 1.77% | +428.05% | Jun 2026 |
| UBS Group AG | 671K | 1.59% | +93.25% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 586K | 1.39% | -10.55% | Jun 2026 |
| Adage Capital Partners Gp LLC | 550K | 1.30% | -50.03% | Jun 2026 |
| State Street Corp | 544K | 1.29% | +631.68% | Jun 2026 |
| Geode Capital Management, LLC | 508K | 1.20% | +185.10% | Jun 2026 |
| Woodline Partners LP | 502K | 1.19% | +0.19% | Jun 2026 |
Veradermics, Incorporated company profile
- Company name
- Veradermics, Incorporated
- Ticker
- MANE.US
- Exchange
- USA Stocks
- Listed since
- Feb 4, 2026
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 51
- Fiscal year end
- December
- Address
- 470 James Street, New Haven, CT, United States, 06513
- Phone
- 228 372 3376
- Website
- veradermics.com
About Veradermics, Incorporated
Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. The company's products include VDPHL01, an oral, non-hormonal treatment for men and women with PHL for chronic hair loss therapy. Additionally, it engages in the development of VDMN, a dissolvable microarray patch technology for immunotherapy of common warts; VDAA for the treatment of alopecia areata; and VDMC for the treatment of molluscum contagiosum. Its products are used for the treatment of androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. The company serves healthcare providers and clinicians treating dermatologic and aesthetic conditions in both adult and pediatric populations, as well as the broader medical and clinical research community involved in dermatology. Veradermics, Incorporated was incorporated in 2019 and is headquartered in New Haven, Connecticut.
Veradermics, Incorporated management
6- Dr. Reid Waldman M.D.CEO & Director · born 1995
- Mr. Dominic Carrano CPACFO & Treasurer · born 1986
- Dr. Timothy Durso M.D.Chief Technical Officer · born 1990
- Mr. Michael V. Greco J.D.General Counsel & Secretary · born 1973
- Mr. Mark NeumannChief Commercial & Strategy Officer · born 1964
- Dr. David A. Hollander M.B.A., M.D.Chief R&D Officer · born 1975